Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE4
INTERVENTIONAL
2016-06-30
2023-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Brief Intervention to Reduce Fear of Public Speaking
NCT02790736
Trial of Low-Dose Xenon For The Treatment Of Obsessive-Compulsive Disorder
NCT02098148
Transcranial Direct Current Stimulation Potentiation of Fear Extinction in OCD
NCT05521074
Efficacy of Nitrous Oxide in OCD: Pilot Study
NCT03826693
Personalized Computerized Inhibitory Control Training for OCD
NCT02378896
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Propanolol
Propranolol 40 mg capsule, given once after fear reactivation procedure
Propanolol
Active treatment
Placebo capsule
Placebo capsule, given once after fear reactivation procedure
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Propanolol
Active treatment
Placebo
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Current Major Depressive Disorder
* Women who are pregnant or nursing
* Current use of psychiatric medication
* Persons planning to start another treatment during the study period
* Any significant medical condition that might increase the risk or participation or use of medications that might negatively interact with propranolol
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
New York State Psychiatric Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Franklin Schneier
Research Scientist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Blair Simpson, MD
Role: STUDY_DIRECTOR
New York State Psychiatric Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
New York State Psychiatric Institute
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
7293 (OCD)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.